Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/14796
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorMykhalchuk, D.-
dc.contributor.authorPavlovskyi, S.-
dc.contributor.authorPavlovska, M.-
dc.contributor.authorDrozdov, V.-
dc.contributor.authorBlagaia, A.-
dc.date.accessioned2025-02-21T13:42:28Z-
dc.date.available2025-02-21T13:42:28Z-
dc.date.issued2022-
dc.identifier.issnDOI: 10.36740/WLek202212103-
dc.identifier.urihttp://ir.librarynmu.com/handle/123456789/14796-
dc.description.abstractThe aim: To determine the peculiarities of laboratory data concerning blood coagulation and systemic inflammation in COVID-19 patients in three months after discharge and recovery. The state of coagulation, anticoagulation, and fibrinolytic systems, as well as their prognostic value having been well studied in hospitalized COVID-19 patients, their state three months after hospitalization, are not yet well understood. Materials and methods: Methods of randomization, anthropometry, ECG, standard clinical blood testing, immunoenzymometry, immunoanalysis, and primary statistical analysis were used in the study. Anthropometric measurements of patients (n=20), blood samples, blood serum samples, urine samples, and statistical data were the materials of the study. Results: Indices of coagulation and systemic inflammation in studied patients after COVID-19 were obtained (PTT, s ; PATPT, s; Fibrinogen, g/L; Platelets ×109 /L; PCT, ng/mL; DD, μg/L; СRP, mg/L; IL -6, pg/mL; IL -10, pg/mL; Cortisol (nM/L); CIC (IU/mL); Ig A (g/L). Conclusions: Summing up the results obtained, it is possible to assert micro- and macro-vascular thromboses to be common in COVID-19 cases; they are associated with poor prognosis for diseased patients and are not completely investigated; the role of thromboses in COVID-19 course and complications are to be studied as well as the strategies of fibrinolytic therapies for such condition are to be justified. The presence of specific rheological and serological changes in patients even three months after surviving COVID-19 needs further study to understand the necessity of anti-thrombolytic drug uptake for a relatively long time.uk_UA
dc.language.isoenuk_UA
dc.publisherWiadomości Lekarskie, VOLUME LXXV, ISSUE 12, DECEMBER 2022uk_UA
dc.subjectCOVID-19, Inflammation, Thrombolytic Therapy, Blood Platelets, Immunoglobulins, Interleukinsuk_UA
dc.titleFeatures Of Coagulopathy And Systemic Inflammation In Patients After Covid-19 Infectionuk_UA
dc.title.alternativeFEATURES OF COAGULOPATHY AND SYSTEMIC INFLAMMATION IN PATIENTS AFTER COVID-19 INFECTIONuk_UA
dc.typeArticleuk_UA
Розташовується у зібраннях:Наукові публікації кафедри гігієни та екології

Файли цього матеріалу:
Файл Опис РозмірФормат 
56 - WLek2022121_removed.pdf335,48 kBAdobe PDFПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.